EBCOG Part 1 Random Practice Ques Paper F(E.M.Q) EBCOG Part 1 Random Practice Ques Paper F(E.M.Q) Name A. Stage 1AB. Stage 1BC. Stage 2D. Stage 3A 1E. Stage 3A 2F. Stage 3B 1G. Stage 3B 2H. Stage 3CI. Stage 4A 1J. Stage 4A 2K. Stage 4B 1. Squamous carcinoma of the vulva, which is 1cm in diameter with a solitary nodal mass in the left internal iliac region suggesting metastasis. Please select your answer A. Stage 1A B. Stage 1B C. Stage 2 D. Stage 3A 1 E. Stage 3A 2 F. Stage 3B 1 G. Stage 3B 2 H. Stage 3C I. Stage 4A 1 J. Stage 4A 2 K. Stage 4B 2. A single 1.8 cm midline vulval lesion at the forchette with 0.9 mm stromal invasion. There are no palpable lymph nodes. Please select your answer A. Stage 1A B. Stage 1B C. Stage 2 D. Stage 3A 1 E. Stage 3A 2 F. Stage 3B 1 G. Stage 3B 2 H. Stage 3C I. Stage 4A 1 J. Stage 4A 2 K. Stage 4B 3. A 4 cm midline vulval tumour invading 3mm into the lower urethra. Please select your answer A. Stage 1A B. Stage 1B C. Stage 2 D. Stage 3A 1 E. Stage 3A 2 F. Stage 3B 1 G. Stage 3B 2 H. Stage 3C I. Stage 4A 1 J. Stage 4A 2 K. Stage 4B 4. A 4 cm midline vulval tumour invading 3mm into underlying stroma only. Please select your answer A. Stage 1A B. Stage 1B C. Stage 2 D. Stage 3A 1 E. Stage 3A 2 F. Stage 3B 1 G. Stage 3B 2 H. Stage 3C I. Stage 4A 1 J. Stage 4A 2 K. Stage 4B 5.A 2.5 cm right vulval mass with one left inguino-femoral node metastasis of 5mm diameter. Please select your answer A. Stage 1A B Stage 1B C. Stage 2 D. Stage 3A 1 E. Stage 3A 2 F. Stage 3B 1 G. Stage 3B 2 H. Stage 3C I. Stage 4A 1 J. Stage 4A 2 K. Stage 4B 6. A 2.5 cm tight vulval mass with two left inguino-femoral node metastasis of 5mm diameter. Please select your answer A. Stage 1A B. Stage 1B C. Stage 2 D. Stage 3A 1 E. Stage 3A 2 F. Stage 3B 1 G. Stage 3B 2 H. Stage 3C I. Stage 4A 1 J. Stage 4A 2 K. Stage 4B A.Alendronic acidB. Insertion of LNG-IUSC. Local vaginal oestrogen therapyD. Medroxy progesterone acetateE. Oral combined cyclical HRTF. Oral phytoestrogensG. RaloxifenH. SSRI antidepressantsI. Sildenafil citrateJ. Testosterone supplementation with systemic HRTK. TiboloneL. Transdermal oestrogen-only HRT 7.A 57-yr old woman suffering from severe menopausal vasomotor and lower genital tract symptoms; last period 12 months ago and known large uterine fibroids. Please select your answer A. Alendronic acid B. Insertion of LNG-IUS C. Local vaginal oestrogen therapy D. Medroxy progesterone acetate E. Oral combined cyclical HRT F. Oral phytoestrogens G. Raloxifen H. SSRI antidepressants C. Local vaginal oestrogen therapy D. Medroxy progesterone acetate E. Oral combined cyclical HRT F. Oral phytoestrogens G. Raloxifen H. SSRI antidepressants I. Sildenafil citrate J. Testosterone supplementation with systemic HRT K. Tibolone L. Transdermal oestrogen-only HRT 8. A 56-yr old woman with a history of breast cancer, on aromatase inhibitors, with a 6 months history of distressing night sweats. Please select your answer A. Alendronic acid B. Insertion of LNG-IUS C. Local vaginal oestrogen therapy D. Medroxy progesterone acetate E. Oral combined cyclical HRT F. Oral phytoestrogens G. Raloxifen H. SSRI antidepressants I. Sildenafil citrate J. Testosterone supplementation with systemic HRT K. Tibolone L. Transdermal oestrogen-only HRT 9. A 58-yr old woman who has had a hysterectomy with diagnosed hypoactive sexual desire disorder (HSDD). Please select your answer A. Alendronic acid B. Insertion of LNG-IUS C. Local vaginal oestrogen therapy D. Medroxy progesterone acetate E. Oral combined cyclical HRT F. Oral phytoestrogens G. Raloxifen H. SSRI antidepressants I. Sildenafil citrate J. Testosterone supplementation with systemic HRT K. Tibolone L. Transdermal oestrogen-only HRT 10.A 65-yr old nulliparous woman (normal BMI) with a history of breast cancer, now presenting with osteoporosis. Please select your answer A. Alendronic acid B. Insertion of LNG-IUS C. Local vaginal oestrogen therapy D. Medroxy progesterone acetate E. Oral combined cyclical HRT F. Oral phytoestrogens G. Raloxifen H. SSRI antidepressants I. Sildenafil citrate J. Testosterone supplementation with systemic HRT K. Tibolone L. Transdermal oestrogen-only HRT 11. A 30-yr old nulliparous woman has been diagnosed with severe endometriosis. She has been commenced on long-term LHRH-A treatment. Please select your answer A. Alendronic acid B. Insertion of LNG-IUS C. Local vaginal oestrogen therapy D. Medroxy progesterone acetate E. Oral combined cyclical HRT F. Oral phytoestrogens G. Raloxifen H. SSRI antidepressants I. Sildenafil citrate J. Testosterone supplementation with systemic HRT K. Tibolone L. Transdermal oestrogen-only HRT 12. A 42-yr old multiparous woman with a history of cervical carcinoma, treated with surgery and radiotherapy. She is now complaining of dyspareunia. Please select your answer A. Alendronic acid B. Insertion of LNG-IUS C. Local vaginal oestrogen therapy D. Medroxy progesterone acetate E. Oral combined cyclical HRT F. Oral phytoestrogens G. Raloxifen H. SSRI antidepressants I. Sildenafil citrate J. Testosterone supplementation with systemic HRT K. Tibolone L. Transdermal oestrogen-only HRT A. Clinical auditB. Clinical effectivenessC. Clinical governanceD. Education and trainingE. JusticeF. OpennessG. Patient and public involvementH. Research and developmentI. Risk managementJ. Staffing and staff managementK. Using information and IT 13. A measure of the extent to which a particular intervention works. Please select your answer A. Clinical audit B. Clinical effectiveness C. Clinical governance D. Education and training E. Justice F. Openness G. Patient and public involvement H. Research and development I. Risk management J. Staffing and staff management K. Using information and IT 14. Processes which are open to public scrutiny, while respecting individual patient and practitioner confidentiality and which can be justified openly. Please select your answer A. Clinical audit B. Clinical effectiveness C. Clinical governance D. Education and training E. Justice F. Openness G. Patient and public involvement H. Research and development I. Risk management J. Staffing and staff management K. Using information and IT 15. A framework through which NHS organization are accountable for continually improving the quality of their services and safeguarding high standards of care by creating an environment in which excellence in clinical care will flourish. Please select your answer A. Clinical audit B. Clinical effectiveness C. Clinical governance D. Education and training E. Justice F. Openness G. Patient and public involvement H. Research and development I. Risk management J. Staffing and staff management K. Using information and IT 16. The review of clinical performance, the refining of clinical practice as a result and the measurement of performance against agreed standards – a cyclical process of improving the quality of clinical care. Please select your answer A. Clinical audit B. Clinical effectiveness C. Clinical governance D. Education and training E. Justice F. Openness G. Patient and public involvement H. Research and development I. Risk management J. Staffing and staff management K. Using information and IT 17. The identification, assessment, and prioritization of risks, followed by coordinated and economical application and resources to minimize, monitor and control the probability and/or impact of unfortunate events. Please select your answer A. Clinical audit B. Clinical effectiveness C. Clinical governance D. Education and training E. Justice F. Openness G. Patient and public involvement H. Research and development I. Risk management J. Staffing and staff management K. Using information and IT A. AmitriptylineB. Anterior colporrhaphyC. Artificial urinary sphincterD. Augmentation cystoplastyE. Botulinum A toxinF. CimetidineG. Colposuspension (Bursh)H. Intraurethral NASHA/DX copolymer injectionI. Needle suspensionJ. Rectus fascia pubovaginal slingK. Sacral neuromodulationL. TOTM. TVTN. Urinary diversion 18. An 83-yr old woman in poor medical health with urodynamic stress incontinence and normal voiding parameters. Please select your answer A. Amitriptyline B. Anterior colporrhaphy C. Artificial urinary sphincter D. Augmentation cystoplasty E. Botulinum A toxin F. Cimetidine G. Colposuspension (Bursh) H. Intraurethral NASHA/DX copolymer injection I. Needle suspension J. Rectus fascia pubovaginal sling K. Sacral neuromodulation L. TOT M. TVT N. Urinary diversion 19. A 44-yr old woman with urge incontinence and severe detrusor overactivity on urodynamic assessment. This is unresponsive to conservative therapy and anticholinergic medication. Please select your answer A. Amitriptyline B. Anterior colporrhaphy C. Artificial urinary sphincter D. Augmentation cystoplasty E. Botulinum A toxin F. Cimetidine G. Colposuspension (Bursh) H. Intraurethral NASHA/DX copolymer injection I. Needle suspension J. Rectus fascia pubovaginal sling K. Sacral neuromodulation L. TOT M. TVT N. Urinary diversion 20. A 56-yr old woman with urodynamic stress incontinence and no previous surgery; her family is complete and there is no prolapse on examination. Please select your answer A. Amitriptyline B. Anterior colporrhaphy C. Artificial urinary sphincter D. Augmentation cystoplasty E. Botulinum A toxin F. Cimetidine G. Colposuspension (Bursh) H. Intraurethral NASHA/DX copolymer injection I. Needle suspension J. Rectus fascia pubovaginal sling K. Sacral neuromodulation L. TOT M. TVT N. Urinary diversion Time's up monisha2021-05-10T04:10:27+00:00